Other manufacturing industries
ORBIO Corporation
ORBIO Corporation
Based on the original discovery that L-glucose, which is extremely rare in nature, is selectively taken up by cancers, we have developed a completely new molecular device of the "Trojan horse" type using L-glucose as the "horse" to cure pancreatic cancer and other intractable cancers. Two cancer biomarkers and two anti-cancer drugs have been developed, and their remarkable efficacy has been verified in vitro and in vivo experiments. We hold 44 patents in Japan, the U.S., Europe, and China, giving us an unparalleled advantage in the world.
Area of Interest
Site-visit
SDGs we are working on
Registered Keyword
Area of Interest
- North America
- Europe
Site-visit
Allowed or subject to conditions
SDGs we are working on
3.Good health and well-being
Registered Keyword
We have three products; 2-NBDLG, CLG and ALG, carrying NBD, coumarin and Au compound as "functional molecules" respectively. The 2-NBDLG and CLG act as green and blue fluorescent biomarkers, and the CLG and ALG act as anti-cancer agents. We showed that the biomarker 2-NBDLG detects cancer cells with high accuracy at the single-cell level in human gastric, ovarian, uterine, bladder, and other cancers by in vitro diagnosis. The anti-cancer drug CLG inhibits the growth of cancer cells by causing coumarin to be incorporated into the nuclei of the cancer cells. Furthermore, as a result of animal experiments, we found that local progression and distant metastasis of pancreatic cancer was significantly inhibited by CLG. Another anti-cancer drug ALG, which uses Au compound as the payload, enters the cancer cell by L-glucose, and causes cell death by Au compounds. In addition, radiofrequency irradiation heats only the cancer cells containing Au and give rise to the hyperthermia effects.